Aminov Erez 5

5 · MIRA PHARMACEUTICALS, INC. · Filed Feb 17, 2026

Form 5

Period: 2025-12-31

DirectorCEO and Chairman

Transactions

Award
Common Stock
[F1][F2]
2025-03-26$1.45/sh+62,500$90,625→ 3,530,166 total
Award
Common Stock
[F1][F2]
2025-03-26$1.45/sh+62,500$90,625→ 3,592,666 total
Exercise/Conversion
Common Stock
[F1][F3]
2025-10-16$1.16/sh+234,595$272,130→ 3,827,259 total
Exercise/Conversion
Common Stock
[F1][F4]
2025-10-16$0.84/sh+379,000$318,360→ 4,206,259 total
Sale
Common Stock
[F1]
2025-10-16$2.11/sh−613,595$1,294,685→ 3,592,666 total
Exercise/Conversion
Stock Options (right to buy)
[F3]
2025-10-16+234,595→ 234,595 total
Exercise: $1.16From: 2025-10-16Exp: 2034-03-26→ Common Stock
Exercise/Conversion
Stock Options (right to buy)
[F4]
2025-10-16+379,000→ 379,000 total
Exercise: $0.84From: 2025-10-16Exp: 2034-05-28→ Common Stock (379,000 underlying)
Award
Stock Options (right to buy)
[F1][F5]
2025-12-17+3,155,170→ 3,155,170 total
Exercise: $1.45Exp: 2035-12-17→ Common Stock (3,155,170 underlying)

Footnotes (5)

[F1]Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.
[F2]Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance.
[F3]Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each.
[F4]Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each.
[F5]Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance.

Signature

/s/ Erez Aminov|2026-02-17

Documents

1 file